Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of safety, efficacy, PK and PD of BG9924 in RA patients who have had an inadequate response to conventional DMARD therapy

Next Previous
Trial Profile

Assessment of safety, efficacy, PK and PD of BG9924 in RA patients who have had an inadequate response to conventional DMARD therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baminercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RESPOND; RESPOND-EXT
  • Sponsors Biogen

Most Recent Events

  • 16 Oct 2009 Preliminary results were presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals.
  • 09 Jan 2009 Extension study status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
  • 09 Jan 2009 Extension study status changed from recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top